Research: Access to HCV Therapy for Patients with Mental Health or Substance Use Disorders

Published by HepCAP on

Has Access to Hepatitis C Virus Therapy Changed for Patients with Mental Health or Substance Use Disorders In The Direct-Acting-Antiviral Period?

Direct‐acting antivirals (DAA) for hepatitis C virus (HCV) became available in 2014, but the role of mental health or substance use disorders (MH/SUD) on access to treatment is unknown. The objective of this study was to examine the extent and predictors of HCV treatment in the pre‐DAA and post‐DAA periods in four large, diverse health care settings in the United States. This study showed that the volume of patients treated for HCV has increased, but disparities in access to treatment continue among those with mental health/substance use disorder.

Click here to read the full article!

Categories: Research

Related Posts

Research

Research: Opportunities to Improve Opioid Use Disorder and Infectious Disease Services: Integrating Responses to a Dual Epidemic (from NASEM)

Conducted at the request of the Department of Health and Human Services’ Office of Infectious Disease and HIV/AIDS Policy (OIDP), this report identifies the barriers to greater integration of OUD and infectious disease services and Read more…

Research

Research: The CDC 2017 Viral Hepatitis Surveillance Report: Takeaways and Highlights

On September 10, 2019, the Centers for Disease Control and Prevention (CDC) released their 2017 Viral Hepatitis Surveillance Report. The report comes after the World Health Assembly in 2016, where the United States agreed to Read more…

Research

Public Comment: US Preventive Service Task Force, Hepatitis C Screening

The U.S. Preventive Services Task Force seeks comments on a draft recommendation statement and draft evidence review on screening for hepatitis C virus infection in adolescents and adults. The Draft Recommendation Statement and Draft Evidence Read more…